Heidy Agustin
Universitas Indonesia

Published : 2 Documents Claim Missing Document
Claim Missing Document

Found 2 Documents

Corona Virus Disease 2019 Diah Handayani; Dwi Rendra Hadi; Fathiyah Isbaniah; Erlina Burhan; Heidy Agustin
Jurnal Respirologi Indonesia Vol 40, No 2 (2020)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v40i2.101


Corona virus disease 2019 (COVID-19) is a new name given by World Health Organization (WHO) of 2019 novel corona virus infection, reported at the end of 2019 from Wuhan, Cina. The spread of infection occurs rapidly and creates a new pandemic threat. Etiology of COVID-19 was identified in 10 January 2020, a betacorona virus, similar with severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS CoV). The clue diagnosis pathway of COVID-19 were history of travel from Wuhan or others infected countries within 14 days prior, and symptoms of acute respiratory illness (ARI) or lower respiratory infection (pneumonia) with the result of real time polymerase chain reaction (RT-PCR) specific for COVID-19. The WHO classified COVID-19 into suspect case, probable case and confirmed case. Indonesia Ministry of Health classified the case into in monitoring (ODP), patient under surveillance (PDP), people without symptom (OTG) and confirmed case. Specimens for detection COVID-19 could be acquired from nasal and nasopharynx swab, sputum and another lower respiratory aspirate including broncoalveolar lavage (BAL). Management of COVID-19 consist of isolation and infection control, supportive treatment according to the disease severity which could be mild (acute respiratory infection) to severe pneumonia or acute respiratory distress syndrome (ARDS). Disease transmission is via droplets and contact with droplets. Currently, there is no antiviral and vaccine. Prevention is very important for this disease by limitation of transmission, identification and isolate patients. Prognosis is determined by severity of the disease and patient comorbidity. Information about this novel disease remains very few, studies are still ongoing and is needing further research to fight with this new virus. (J Respir Indo. 2020; 40(2): 120-30)
The Prevalens of Ototoxicity in Drug Resistance Tuberculosis Patients and The Associated Factors at Persahabatan General Central Hospital Ismulat Rahmawati; Fathiyah Isbaniah; Heidy Agustin; Raden Ena Sarikencana
Jurnal Respirologi Indonesia Vol 39, No 3 (2019)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1034.14 KB) | DOI: 10.36497/jri.v39i3.62


Background: The treatment of drug resistance tuberculosis needs second line injection antituberculosis drug that associated with irreversible ototoxic. The aim of this study is to know the prevalence of ototoxicity in tuberculosis drug resistance patients and the contributing factors. Methods: This is a cross sectional study among drug resistance TB patients who receive kanamysin or capreomycin as a part of drug regimen during intensive phase in January to September 2017 at Persahabatan hospital. Ototoxic defined according to American Speech Language and Hearing Association (ASHA) 1994 criteria by comparing baseline audiometric examination before treatment with current result. Results: Seventy-two patients were included in this study. The prevalence of ototoxicity was found in 34 patients (47,2%). Ototoxic found in 5 subjects (14,7%) during the first month of treatment and 19 subjects (56%) without hearing disturbance complain. Ototoxic in kanamisin group (47,9%) is more frequent compared with capreomisin (36,8%). Ototoxicity was associated with age, the risk increases 5% every 1 year older p=0,029 aOR:1,050 IK95% (1,005-1,096). The prevalences of ototoxicity are higher in diabetes and increasing serum creatinin patients but statistically not significance. Sex, body mass index, the history of using injectable antiTB drug, HIV status and total dosis were not associated with ototoxicity. Conclusion: Ototoxicity is common in intensive phase of drug resistance tuberculosis treatment. Further study needed to determine the association of contributing factors. (J Respir Indo. 2019; 39(3):180-95)